---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-048173"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T23:02:59.005439+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience FY2024 rev $313.0M (+28% YoY); Q4 gross margin 45.1%; FY2025 rev guidance $367M-$377M

## Summary
- FY2024 revenue $313.0M, up 28% vs FY2023; Q4FY24 revenue $84.7M, up 27% YoY, 7th consecutive sequential growth.
- Gross margin improved to 45.1% in Q4FY24 (from 36.6%); net loss narrowed to $34.7M ($0.59/share) from $46.2M ($0.81/share).
- FY2025 guidance: revenue $367M-$377M; targeting 50% gross margin by Q4FY25.
- Adjusted EBITDA improved to -$93.5M FY2024 vs -$147.3M FY2023; cash $276.4M at year-end.
- Entered $15M royalty purchase agreement with XOMA; launched FlexPrep NGS kit with proprietary enzyme.

## SEC filing metadata
- accession: 0001628280-24-048173
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000162828024048173/0001628280-24-048173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000162828024048173/twist-20241118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-048173
- JSON: https://secwatch.observer/filing/0001628280-24-048173.json
- Plain text: https://secwatch.observer/filing/0001628280-24-048173.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.